Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 124

1.

Effect of anesthetics on microglial activation and nanoparticle uptake: Implications for drug delivery in traumatic brain injury.

Kannan G, Kambhampati SP, Kudchadkar SR.

J Control Release. 2017 Mar 20. pii: S0168-3659(17)30143-8. doi: 10.1016/j.jconrel.2017.03.032. [Epub ahead of print]

PMID:
28336376
2.

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.

Tolcher AW, Berlin JD, Cosaert J, Kauh J, Chan E, Piha-Paul SA, Amaya A, Tang S, Driscoll K, Kimbung R, Kambhampati SR, Gueorguieva I, Hong DS.

Cancer Chemother Pharmacol. 2017 Apr;79(4):673-680. doi: 10.1007/s00280-017-3245-5. Epub 2017 Mar 9.

PMID:
28280971
3.

Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation.

Soiberman U, Kambhampati SP, Wu T, Mishra MK, Oh Y, Sharma R, Wang J, Al Towerki AE, Yiu S, Stark WJ, Kannan RM.

Biomaterials. 2017 May;125:38-53. doi: 10.1016/j.biomaterials.2017.02.016.

PMID:
28226245
4.

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.

LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SR, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J, Kauh J, Chiorean EG.

Invest New Drugs. 2017 Feb 4. doi: 10.1007/s10637-016-0413-0. [Epub ahead of print]

PMID:
28161886
5.

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.

Khalil DN, Postow MA, Ibrahim N, Ludwig DL, Cosaert J, Kambhampati SR, Tang S, Grebennik D, Kauh JS, Lenz HJ, Flaherty KT, Hodi FS, Lawrence DP, Wolchok JD.

Clin Cancer Res. 2016 Nov 1;22(21):5204-5210.

PMID:
27797971
6.

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.

Reed GA, Schiller GJ, Kambhampati S, Tallman MS, Douer D, Minden MD, Yee KW, Gupta V, Brandwein J, Jitkova Y, Gronda M, Hurren R, Shamas-Din A, Schuh AC, Schimmer AD.

Cancer Med. 2016 Nov;5(11):3031-3040. doi: 10.1002/cam4.845.

7.

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.

Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K, Alcindor T, Jeyakumar A, Chan T, Rao S, Spratlin J, Tang PA, Rothenstein J, Chan E, Bendell J, Kudrik F, Kauh J, Tang S, Gao L, Kambhampati SR, Nasroulah F, Yang L, Ramdas N, Binder P, Strevel E.

Ann Oncol. 2016 Dec;27(12):2216-2224. doi: 10.1093/annonc/mdw412.

PMID:
27733377
8.

Ileus is a predictor of local infection in patients with acute necrotizing pancreatitis.

Moran RA, Jalaly NY, Kamal A, Rao S, Klapheke R, James TW, Kambhampati S, Makary MA, Hirose K, Kumbhari V, Stein EM, Khashab MA, Lennon AM, Kalloo AN, Zaheer A, Hernaez R, Singh VK.

Pancreatology. 2016 Nov - Dec;16(6):966-972. doi: 10.1016/j.pan.2016.10.002.

PMID:
27727097
9.

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.

Saif MW, Knost JA, Chiorean EG, Kambhampati SR, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH.

Cancer Chemother Pharmacol. 2016 Oct;78(4):815-24. doi: 10.1007/s00280-016-3134-3.

PMID:
27566701
10.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.

Novello S, Scagliotti G, de Castro G Jr, Kiyik M, Kowalyszyn R, Deppermann KM, Arriola E, Bosquee L, Novosiadly RD, Nguyen TS, Forest A, Tang S, Kambhampati SR, Cosaert J, Reck M.

J Thorac Oncol. 2017 Feb;12(2):383-389. doi: 10.1016/j.jtho.2016.07.013.

11.

Surface functionality affects the biodistribution and microglia-targeting of intra-amniotically delivered dendrimers.

Zhang F, Nance E, Zhang Z, Jasty V, Kambhampati SP, Mishra MK, Burd I, Romero R, Kannan S, Kannan RM.

J Control Release. 2016 Sep 10;237:61-70. doi: 10.1016/j.jconrel.2016.06.046.

PMID:
27378700
12.

Myelodysplastic Syndrome with concomitant t(5;21)(q15;q22) and del(5)(q13q33): case report and review of literature.

Kasi Loknath Kumar A, Weckbaugh B, Sirridge C, Woodroof J, Persons D, Kambhampati S.

Stem Cell Investig. 2016 Feb 23;3:3. doi: 10.3978/j.issn.2306-9759.2016.02.01.

13.

Sebaceous cell carcinoma developing in epidermodysplasia verruciformis.

Kambhampati SB, Vinay K, De D, Handa S, Gaspar BL, Saikia UN.

Indian J Dermatol Venereol Leprol. 2016 Jul-Aug;82(4):433-5. doi: 10.4103/0378-6323.175909. No abstract available.

14.

Nanoscale effects in dendrimer-mediated targeting of neuroinflammation.

Nance E, Zhang F, Mishra MK, Zhang Z, Kambhampati SP, Kannan RM, Kannan S.

Biomaterials. 2016 Sep;101:96-107. doi: 10.1016/j.biomaterials.2016.05.044.

PMID:
27267631
15.

Shared Decision-Making and Patient Empowerment in Preventive Cardiology.

Kambhampati S, Ashvetiya T, Stone NJ, Blumenthal RS, Martin SS.

Curr Cardiol Rep. 2016 May;18(5):49. doi: 10.1007/s11886-016-0729-6. Review.

PMID:
27098670
16.

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR; ONTIME study investigators..

Lancet Oncol. 2016 Apr;17(4):496-508. doi: 10.1016/S1470-2045(16)00009-7.

PMID:
26968357
17.

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Lancet Haematol. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0.

PMID:
26686043
18.

Unified framework for triaxial accelerometer-based fall event detection and classification using cumulants and hierarchical decision tree classifier.

Kambhampati SS, Singh V, Manikandan MS, Ramkumar B.

Healthc Technol Lett. 2015 Aug 3;2(4):101-7. doi: 10.1049/htl.2015.0018.

19.

Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.

Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A.

Leukemia. 2016 Mar;30(3):536-44. doi: 10.1038/leu.2015.297. Review.

PMID:
26500138
20.

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.

Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, Cogle CR, Edenfield WJ, Hetzer J, Kumar K, Laille E, Shi T, MacBeth KJ, Skikne B.

Leukemia. 2016 Apr;30(4):889-96. doi: 10.1038/leu.2015.265.

Supplemental Content

Loading ...
Support Center